Results 231 to 240 of about 134,020 (288)

Deciphering the pharmacological mechanism of Radix astragali for allergic rhinitis through network pharmacology and experimental validation. [PDF]

Sci Rep
Hua Y, Tan X, Zhang J, Xu N, Chen R, Zhou S, Liu S, Li K, Chen W, Luo Q, Li Y.   +10 more
europepmc   +1 more source

Discovering broad-spectrum inhibitors for SARS-CoV-2 variants: a cheminformatics and biophysical approach targeting the main protease. [PDF]

Front Pharmacol
Alqahtani SM.
europepmc   +1 more source

Elucidating the multi-target pharmacological mechanism of Xiaoyandina for the treatment of hepatitis C virus based on bioinformatics and cyberpharmacology studies. [PDF]

Medicine (Baltimore)
Dilimulati D, Nueraihemaiti N, Hailati S, Han M, Abudurousuli K, Maihemuti N, Baishan A, Aikebaier A, Abulizi M, Zhou W.   +9 more
europepmc   +1 more source

Risk of colorectal cancer and cancer‐related mortality in type 2 diabetes patients treated with metformin, SGLT‐2 inhibitors, or their combination

Cancer Communications, EarlyView.
Xianhua Mao, Ka‐Shing Cheung, Jing‐Tong Tan, Lung‐Yi Mak, Chi‐Ho Lee, Ho Ming Cheng, Rex Wan‐Hin Hui, Esther Wai Yin Chan, Philip Leung‐Ho Yu, Man‐Fung Yuen, Wai K Leung, Wai‐Kay Seto   +11 more
wiley   +1 more source

PINK1 SUMOylation regulates basal mitophagy

Ramesh NS, Seager R, Wilkinson KA, Henley JM.   +3 more
europepmc   +1 more source

Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor

Blood, 2000
AbstractThe malignant Reed-Sternberg cell of Hodgkin disease is an aberrant B cell that persists in an immunolgically mediated inflammatory infiltrate. Despite its nonproductive immunoglobulin genes, the Reed-Sternberg cell avoids the usual apoptotic fate of defective immune cells through an unknown mechanism. A likely candidate is the surface receptor,
Christina M. Annunziata, Yassamin J. Safiran, Steven G. Irving, Usha N. Kasid, Jeffrey Cossman   +4 more
  +5 more sources

Clinical pharmacologic considerations for HIV-1 protease inhibitors

Current Infectious Disease Reports, 2001
Many data associate low protease inhibitor plasma concentrations with suboptimal virologic responses, whereas relatively few data associate high plasma concentrations with increased likelihood of toxicity. Knowledge of relationships between concentrations and virologic response is important because significant variability in plasma concentrations ...
Peter L. Anderson, Courtney V. Fletcher
openalex   +4 more sources

Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules

Current Opinion in Infectious Diseases, 2002
Antiretroviral agents target HIV replication within infected cells. It is therefore important to focus on the pharmacology of these drugs at their site of action rather than just in plasma. Activation of nucleoside analogues to a triphosphate is essential for antiretroviral activity.
Patrick G. Hoggard, David Back
openalex   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Clinical pharmacology of HIV protease inhibitors in pregnancy

Current Opinion in HIV and AIDS, 2008
The use of highly active antiretroviral therapy during pregnancy has reduced the prevalence HIV of mother-to-child transmission (MTCT) dramatically. At present, the recommended first-line treatment for prevention of MTCT in developed countries is protease inhibitor-based highly active antiretroviral therapy.
Lugt, J. van der, Colbers, A., Burger, D.M.   +2 more
openaire   +4 more sources

Pharmacological enhancement of protease inhibitors with ritonavir: an update

Expert Review of Clinical Pharmacology, 2008
Advances in HIV treatment since the approval of the first antiretroviral (ARV) medication have occurred at a rapid pace. However, resistance to these medications can occur quickly owing to inadequate plasma concentrations resulting from poor adherence related to intolerable drug toxicities and complex dosing schedules.
Kristin Busse, Scott Penzak
openalex   +4 more sources